Screener / SEC EDGAR /CIK 0000883984 /10-K filed Feb 19, 2026, compared with Feb 27, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Medical Instruments

ICU Medical Inc ICUI

Compare with peers Embed
SEC comment letters, last 20 years

3 reviews of ICUI's filings by SEC staff

UPLOAD and CORRESP
Reviews 3 latest letter Oct 25, 2023
Questions asked 12 each answered in the company's own letter
No closing letter 0 reviews without a letter saying the staff completed it

When the SEC's staff reviews a filing, it writes to the company with numbered questions, and the company answers each one in a letter. SEC publishes the exchange once the review is over, at least 20 business days later. A question is not an accusation; most reviews end with the company adding detail to its next filing.

How the reviews went

Every review on EDGAR, from the first staff letter to the letter that closes it

  1. 1. Staff letters 5 UPLOAD
  2. 2. Questions in them 12 numbered comments
  3. 3. Company replies 5 CORRESP
  4. 4. Reviews closed 3 of 3 closing letter

Half the closed reviews took 47 days or less from the first letter to the closing letter.

Form 10-K for the fiscal year ended December 31, 2022

2023-10-25 to 2023-12-15 · 5 questions · 2 letters from the SEC, 2 from the company
Review closed 2023-12-15
RevenueLiquidity and cashNon-GAAP measures
Consolidated Financial Statements · Note 1. Revenue Recognition, page 73
SEC asked (1)
We note you estimate variable consideration related to rebates, chargebacks and product returns. Please provide in future filings the qualitative and quantitative information about the significant judgments and changes in judgments that significantly affect the determination of your transaction price, as set forth in ASC 606-10-50-1(b), 50-17(b), and 50-20(a).
Rest of the question

Please provide us any intended revisions and the calculations used to determine variable consideration for the periods presented.

ICUI answered
United States Securities and Exchange Commission Office of Industrial Applications and Services Form 10-K for the fiscal year ended December 31, 2022 Form 10-Q for the quarterly period ended June 30, 2023 This letter is submitted on behalf of ICU Medical, Inc., a Delaware corporation (the “Company”), with respect to the comments of the Staff (the “Staff”) of the Securities and Exchange Commission contained in the Staff’s letter dated October 25, 2023. For ease of review, we have set forth below, in italics, the numbered comments in the Staff’s letter, followed by the Company’s response thereto.
Rest of the letter

Unless otherwise indicated, capitalized terms used herein have the meanings assigned to them in the applicable filing and all references to page numbers in such responses are to page numbers in such filing. We note you estimate variable consideration related to rebates, chargebacks and product returns. Please provide in future filings the qualitative and quantitative information about the significant judgments and changes in judgments that significantly affect the determination of your transaction price, as set forth in ASC 606-10-50-1(b), 50-17(b), and 50-20(a). Please provide us any intended revisions and the calculations used to determine variable consideration for the periods presented. Response: The Company respectfully acknowledges the Staff’s comment and in response the Company, in future filings, will provide the following revisions (added language as underlined and deleted language as strikethrough) which include additional quantitative and qualitative information related to the calculations used and significant judgments applied that affect the estimation of variable consideration related to wholesaler chargebacks: Payment is typically due in full within 30 days of delivery or the start of the contract term. Revenue is recorded in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. We offer certain volume-based rebates to both our distribution and end customers, which we record as variable consideration when calculating the transaction price. Rebates are offered on both a fixed and tiered/variable basis. In both cases, we use information available at the time, including and current contractual requirements, our historical experience with each customer and forecasted customer purchasing patterns, to estimate the most likely rebate amount. We also provide chargebacks to distributors that sell to end customers at prices determined under a contract between us and the end customer. Chargebacks are the difference between the prices we charge our distribution customers and the contracted prices we have with the end customer which are processed as credits to our distribution customers. Individual chargeback rates can vary significantly depending on the product and contracted prices with distributors and end customers. In estimating the expected value of chargeback amounts in order to when determine determining the transaction price, we generally use a combination of the following information available at the time, including our historical experience.: (i)Actual recent history of chargebacks paid to each distributor determined at either a product or product-family level; and (ii)Inventory balances at distributors for which a chargeback claim is expected to be paid upon future sale to an end customer. On a periodic basis, the Company also uses metrics to evaluate the adequacy of the chargeback reserve including movements in inventory on hand at distributors, trends in accrued versus paid chargebacks and impacts from price changes and similar metrics. The chargeback reserve reflects our best estimate of the amount of consideration using the expected value method and is recorded as a reduction of accounts receivable, net on the consolidated balance sheets along with rebates and product return reserves which are less significant. The value of the chargeback reserve generally represents approximately two months of obligation due to the timing difference between the initial sale to a distributor and the processing of a chargeback claim which occurs after the product is sold to the end customer. You set forth in your disclosure "during the six months ended June 30, 2023, our cash and cash equivalents and short-term investment securities increased by $15.3 million from $213.0 million at December 31, 2022 to $197.7 million at June 30, 2023. This increase was primarily due to cash generated from operations." We note, however, you experienced a decrease during that time frame. Please correct your discussion in future filings. Response: The Company respectfully acknowledges the Staff’s comment and recognizes that the cited discussion reflects a decrease in cash and cash equivalents and short-term investment securities during the relevant period. The discussion in the Company’s most recent Form 10-Q for the quarterly period ended September 30, 2023, filed on November 6, 2023 (the “Q3 Form 10-Q”) correctly reflects this, and the Company will continue to do so in future filings, as applicable. You disclose that "net income plus adjustments for non-cash net expenses contributed $151.7 million." Please tell us whether you consider this reference a non-GAAP measure and how you arrived at this determination. Please provide us any intended revisions to your disclosure, as applicable. Refer to Item 10(e) of Regulation S-K. Response: The Company respectfully acknowledges the Staff’s comment and advises the Staff that the intention of this disclosure was to quantify the impact on operating cash flows resulting from non-cash expenses as compared to changes in operating assets and working capital as these categories tend to be different in nature. However, to avoid misinterpretation, the Company removed the disclosure of net income plus adjustments for non-cash expenses in its Q3 Form 10-Q and advises the Staff that it will not include such disclosure in future filings. Use of Non-GAAP Financial Information, page 6 Please describe for us in further detail the "quality system and product-related remediation" costs and the "quality and regulatory initiatives and remediation" costs incurred during 2022 and 2023, and explain to us how you have considered Non-GAAP Financial Measures Compliance & Disclosure Interpretations 100.01 as part of making an adjustment for these costs in determining your non-GAAP measures. Response: The Company respectfully acknowledges the Staff’s comment and provides the following response. The 2023 quality and regulatory initiatives and remediation costs included (i) incremental costs, primarily product certification, labor, contractor and third-party costs, to develop processes and systems to comply with the European Union Medical Device Regulations (“EU MDR”) and (ii) costs related to quality system remediation and product field corrective actions incurred in response to observations noted in an FDA Warning Letter received by Smiths Medical prior to the Company’s acquisition of Smiths Medical in January 2022. The 2022 quality system and product-related remediation costs were substantially similar to the 2023 costs described in clauses (i) and (ii) in the preceding sentence; however, the Company refined the description in 2023 to more accurately reflect the nature of the costs. When adjusting for costs in determining the Company’s non-GAAP financial measures, the Company evaluates the nature and effect of the excluded costs, specifically how those costs correlate to the Company’s operations, revenue generating activities, business strategy, industry and regulatory environment. Based on those evaluations, the Company considers whether a cost could be viewed as recurring and the exclusion thus misleading. The Company considered the updates in the EU MDR regulations to be a significant change to the existing regulatory framework and believed that the costs of initial compliance for previously registered products were duplicative and not reflective of the Company’s normal operating expenses associated with core operations. For example, requirements of the new regulations included new labeling requirements, new classification rules, new safety and performance requirements, the requirement to have sufficient clinical evidence demonstrating compliance and new requirements for a post-market surveillance system. The Company incurred significant one-time charges in 2023 and 2022 related to the initial implementation of all such requirements. Similarly, the remediation costs incurred for corrective actions as a result of the FDA Warning Letter inherited as part of an acquired business were not considered to be costs which would recur on an ongoing basis. Although the FDA may conduct inspections or audits of the Company facilities at any time, the Company’s normal operations are subject to a high-standard quality control process. The charges related to the development of enhanced quality management systems and processes of Smiths Medical were incurred to bring the acquired business in compliance with the required minimum standards of the Company and the product field corrective actions addressed historical deficiencies resulting from Smiths Medical’s sub-standard quality management system and processes which were outside of the Company’s control prior to acquisition. The Company expects these charges to cease once the EU MDR certification requirements have been met prior to the effective date and when the FDA Warning Letter observations have been fully remediated. The Company reviews the non-GAAP measures regularly to determine whether there warrants a change in characterization of adjustments based on the frequency of the charges incurred. We hope that the foregoing has been responsive to the Staff’s comments and look forward to resolving any outstanding issues as quickly as possible. Please do not hesitate to contact our counsel, Latham & Watkins LLP, by calling Daniel Rees at (714) 755‑2244 with any questions or further comments you may have or if you wish to discuss the above.

One letter for all the questions, without numbered answers. Read the reply
In its next report

First report after the company's reply of Nov 27, 2023: 10-K filed Feb 27, 2024 ↗, against the 10-K filed Feb 27, 2023 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Liquidity and Capital Resources, page 49
SEC asked (2)
You set forth in your disclosure "during the six months ended June 30, 2023, our cash and cash equivalents and short-term investment securities increased by $15.3 million from $213.0 million at December 31, 2022 to $197.7 million at June 30, 2023. This increase was primarily due to cash generated from operations." We note, however, you experienced a decrease during that time frame.
Rest of the question

Please correct your discussion in future filings.

ICUI answered

See the reply above.

In its next report

First report after the company's reply of Nov 27, 2023: 10-K filed Feb 27, 2024 ↗, against the 10-K filed Feb 27, 2023 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Liquidity and Capital Resources, page 49
SEC asked (3)
You disclose that "net income plus adjustments for non-cash net expenses contributed $151.7 million." Please tell us whether you consider this reference a non-GAAP measure and how you arrived at this determination. Please provide us any intended revisions to your disclosure, as applicable. Refer to Item 10(e) of Regulation S-K. Exhibit 99.1
ICUI answered

See the reply above.

In its next report

First report after the company's reply of Nov 27, 2023: 10-K filed Feb 27, 2024 ↗, against the 10-K filed Feb 27, 2023 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Use of Non-GAAP Financial Information, page 6
SEC asked (4)
Please describe for us in further detail the "quality system and product-related remediation" costs and the "quality and regulatory initiatives and remediation" costs incurred during 2022 and 2023, and explain to us how you have considered Non-GAAP Financial Measures Compliance & Disclosure Interpretations 100.01 as part of making an adjustment for these costs in determining your non-GAAP measures.
Rest of the question

In closing, we remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

ICUI answered

See the reply above.

In its next report

First report after the company's reply of Nov 27, 2023: 10-K filed Feb 27, 2024 ↗, against the 10-K filed Feb 27, 2023 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Consolidated Financial Statements · Note 1. Revenue Recognition, page 73
SEC asked
We have reviewed your proposed revised disclosure and response to prior comment 1, and we do not see in the proposed disclosure the judgments made in the application of ASC 606. Please revise your disclosure to identify and explain the judgments and changes in judgments made in applying ASC 606, and also provide the related qualitative and quantitative information, to more fully address the disclosure requirements
Rest of the question

of ASC 60610-50-1(b), 50-17(b), and 50-20(a). Alternatively, describe to us the reasons why further disclosure is not necessary. Please provide us the calculations used to determine variable consideration for the periods presented so that we are able to better understand your application of the ASC 606 disclosure requirements.

ICUI answered
The Company respectfully acknowledges the Staff’s comment and advises the Staff that the Company, in future filings, will provide the following updated revisions (added language as underlined and deleted language as strikethrough) which include additional quantitative and qualitative information related to the calculations used and significant judgments applied that affect the estimation of variable consideration:

Payment is typically due in full within 30 days of delivery or the start of the contract term.
Rest of the answer

Revenue is recorded in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. We include variable consideration in net sales only to the extent that a significant reversal in revenue is not probable when the uncertainty is resolved.

Our variable consideration includes distributor chargebacks, product returns and end customer rebates, with distributor chargebacks representing the majority and subject to the greatest judgment. We also provide chargebacks to distributors that sell to end customers at prices determined under a contract between us and the end customer. In estimating the expected value of chargeback amounts in order determine the transaction price, we use information available at the time, including our historical experience.

Chargebacks are the difference between the prices we charge our distribution customers at the time they purchase our products and the contracted prices we have with the end customer, most often in the U.S, and Canada. When a distributor sells our products to one of our contracted end customers, the distributor typically will claim a refund from us for the chargeback amount which are we processed as a credits to our the distributorn customers. In estimating the transaction price to present as net revenue for sales to distributors, we must estimate the expected chargeback amount that we will refund to the distributor after they sell our product to a contracted end customer. Determining the appropriate chargeback reserve requires judgment around the following assumptions:

(i)The estimated chargeback amount (the difference between the price we invoice the distributor and the contractually agreed price with specified end customers); and

(ii)The estimated period of time between the sale to the distributor and the receipt of a chargeback claim.

For purposes of estimating the expected chargeback amount, we utilize actual recent historical chargebacks paid to the specific distributor for similar products as determined at either a product or product-family level. While individual chargeback rates can vary significantly depending on the product and contracted prices with distributors and end customers, our chargeback reserve estimate is not overly sensitive to those individual price changes due to the long-term nature of our distributor and end customer contracts as well as consistency in purchasing patterns. Additionally, the use of the actual chargeback history to calculate an average chargeback rate has historically resulted in a reasonable estimation of overall current contract rates.

For purposes of estimating the period of time between the sale to the distributor and the receipt of a chargeback claim, we utilize several sources of information including actual inventory quantities of our products on hand at distributors. This inventory on hand information is received from the distributors or, when specific quantities are not provided, estimated by using the targeted days of inventory on hand for distributors. Historical experience of actual chargebacks paid has indicated that use of this information has reasonable predictive value of outstanding chargebacks and accounts for the variability of purchasing patterns and expected timing and volume of sales to end customers. The value of the chargeback reserve generally represents approximately two months of obligation due to the timing difference between the initial sale to a distributor and the processing of a chargeback claim after the product is sold to the end customer.

The chargeback reserve estimates change from period-to-period primarily based on changes in revenue from/and the inventory levels of distributors. Our judgments regarding the information used to calculate the chargeback reserve are consistent from period to period, however, on a regular basis, we evaluate the adequacy of the chargeback reserve to reassess and ensure that the variable consideration is appropriately constrained, and the likelihood of future revenue reversal is not probable. We use metrics including chargeback provision as a percentage of gross revenue, movements in inventory on hand at distributors, trends in accrued versus paid chargebacks and impacts from price changes and similar metrics.

The chargeback reserve reflects a reasonable estimate of the amount of consideration using the expected value method and is recorded as a reduction of accounts receivable, net on the consolidated balance sheets.

We also offer certain volume-based rebates to both our distribution and end-customers, which we record as variable consideration when calculating the transaction price. Rebates are offered on both a fixed and tiered/variable basis. In both cases, we use information available at the time, including and current contractual requirements, our historical experience with each customer and forecasted customer purchasing patterns, to estimate the most likely rebate amount.

* * *

We hope that the foregoing has been responsive to the Staff’s comments and look forward to resolving any outstanding issues as quickly as possible. Please do not hesitate to contact our counsel, Latham & Watkins LLP, by calling Daniel Rees at (714) 755‑2244 with any questions or further comments you may have or if you wish to discuss the above.

Read in the reply
In its next report

First report after the company's reply of Dec 14, 2023: 10-K filed Feb 27, 2024 ↗, against the 10-K filed Feb 27, 2023 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Also in this review: closing letter, 2023-12-15

Form 10-K for the Fiscal Year Ended December 31, 2016

2017-07-27 to 2017-09-12 · 5 questions · 2 letters from the SEC, 2 from the company
Review closed 2017-09-12
Acquisitions
Item 1. Financial Statements · Note 3. Acquisitions and Strategic Transaction Expenses, page 10
SEC asked (1)
Your disclosure attributes the significant bargain purchase gain to a potential future restructuring that could not be recorded in accounting for the acquisition. Please clarify for us the factors you considered in concluding that the bargain purchase gain is related to the potential for a future restructuring rather than the low fair value assigned to the contingent consideration.
Rest of the question

Also, please clarify the meaning of the reference to the “current level of sales demand” in your disclosure and how that matter impacted the fair value of the contingent consideration.

ICUI answered
The primary factor that the Company considered in concluding that the bargain purchase gain on the assets acquired and liabilities assumed with the Hospira Infusion System business (the “HIS business”) was related to the potential for a future restructuring (including costs of standing up the acquired assets of the HIS business and other related costs, some of which are described below), was the shortfall in HIS product demand in the market (which the Company referred to in its Form 10-Q for the quarterly period ended March 31, 2017 as “level of sales demand”), as compared to product sale
Rest of the answer

forecasts of the HIS business at the time that the purchase price was agreed upon.

On October 6, 2016, the Company agreed to acquire the HIS business for approximately $1 billion. At that time, the Company noted in investor presentations that it estimated $75 million in Adjusted EBITDA from the HIS business in 2017. After continuing review of the product demand and operations of the HIS Business, on January 5, 2017, the Company and Pfizer agreed to amend the terms of the definitive agreement to among other things, a) reduce the upfront purchase price by $325 million and b) provide for an earnout of up to $225 million. In connection with this amendment, the Company provided an update to its forecast for Adjusted EBITDA from the HIS business in 2017 to $35 - 40 million, citing revenue shortfalls across all market segments of the HIS business, negative manufacturing variance due to the drop in revenue and higher operating and required stand up costs. The Company noted at such time that it’s pro forma combined EBITDA forecast dropped from a run rate in 2018 of approximately $300 million, to $250 million. This decline in anticipated product demand necessitated, among other things, that the Company terminate employees, close a manufacturing facility and transfer assets and production to Costa Rica and to its existing plant in Ensenada, Mexico. These restructuring changes resulted in severance costs related to involuntary employee terminations, transfer costs and facility exit costs related to the closure of the Dominican Republic manufacturing facilities acquired from Pfizer, in addition to other stand up costs.

The fair value assigned to the contingent consideration was carefully evaluated by the Company and the factors and analysis in this determination are described in the Company’s Form 10-Q for the quarterly period ended June 30, 2017, filed August 9, 2017. See Item 1. Notes to Condensed Consolidated Financial Statements, Note 7: Fair Value Measurement.

Read in the reply
In its next report

First report after the company's reply of Aug 10, 2017: 10-Q filed Nov 9, 2017 ↗, against the 10-Q filed May 12, 2017 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Note 7. Fair Value Measurement, page 13
SEC asked (2)
With respect to the contingent consideration recorded on the acquisition of HIS, in future filings please expand to disclose quantitative information about the significant unobservable inputs underlying the level 3 fair value measurement. Refer to ASC 82010-50-2bbb.
ICUI answered
The Company acknowledges the Staff’s comment and has expanded the disclosure in the Company’s Form 10-Q for the quarterly period ended June 30, 2017, filed August 9, 2017, with the quantitative information about the significant unobservable inputs underlying the level 3 fair value measurement, and will continue to do so in future filings, as applicable. See Item 1. Notes to Condensed Consolidated Financial Statements, Note 7: Fair Value Measurement.
Read in the reply
In its next report

First report after the company's reply of Aug 10, 2017: 10-Q filed Nov 9, 2017 ↗, against the 10-Q filed May 12, 2017 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Exhibit 99.1
SEC asked (3)
Please amend the financial statements to include an audit report that expresses an opinion on all three periods presented. In this regard, we note that the opinion paragraph does not address the year ended December 31, 2014.
ICUI answered
The Company acknowledges the Staff’s comment and advises the Staff that the Company has amended it’s filing on Form 8-K/A on August 10, 2017 to correct the typographical error and include an audit report that expresses an opinion on the three periods presented.

* * * * *

We hope the foregoing has been responsive to the Staff’s comments and look forward to resolving any outstanding issues as quickly as possible. Please do not hesitate to contact me at 949-366-4227 with any questions or further comments you have regarding this filing or if you wish to discuss the above.
Read in the reply
In its next report

First report after the company's reply of Aug 10, 2017: 10-Q filed Nov 9, 2017 ↗, against the 10-Q filed May 12, 2017 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Note 3. Acquisitions and Strategic Transaction Expenses, page 10
SEC asked (1)
We refer to your response to comment 1. Please expand the notes to future financial statements to qualitatively describe the business and operational factors leading to the reduction in the fixed purchase price and low value assigned to the contingent consideration as described in your response. Refer to ASC 805-30-50-1f.
ICUI answered
The Company acknowledges the Staff’s comment and advises the Staff that the Company will include a description consistent with these instructions in future financial statements
Read in the reply
In its next report

First report after the company's reply of Sep 5, 2017: 10-Q filed Nov 9, 2017 ↗, against the 10-Q filed May 12, 2017 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Note 3. Acquisitions and Strategic Transaction Expenses, page 10
SEC asked (2)
As a related matter, we note your disclosure continues to attribute the $63 million bargain purchase gain to a potential future restructuring. Please revise future filings to clarify that disclosure in light of statements in Note 4 indicating that restructuring charges of $16 million recognized in the first six months of 2017 represent all material charges related to integrating HIS into your business.
ICUI answered
The Company respectfully acknowledges the Staff’s comment and advises the Staff that the Company will revise future filings accordingly.

* * * * *

We hope the foregoing has been responsive to the Staff’s comments. Please do not hesitate to contact me at 949-366-4227 with any questions or further comments you have regarding this filing or if you wish to discuss the above.
Read in the reply
In its next report

First report after the company's reply of Sep 5, 2017: 10-Q filed Nov 9, 2017 ↗, against the 10-Q filed May 12, 2017 ↗.

Tickdelta does not hold the text of both reports, so they are not compared here.

Also in this review: closing letter, 2017-09-12

Form 10-K

2016-06-27 to 2016-07-19 · 2 questions · 1 letter from the SEC, 1 from the company
Review closed 2016-07-19
RevenueRussia and Ukraine
General
SEC asked (1)
You refer on page 7 of the 10-K to sales and sales support personnel serving Africa and the Middle East, regions that include Sudan and Syria. You state on pages 3 and 12 of the 10-K that sales to Pfizer accounted for 36% of your revenues for the year ended December 31, 2015.
Rest of the question

We are aware of a 2015 article stating that Pfizer provided exclusive funding for a program that engaged in lobbying and advocacy in Sudan and worked with the government of Sudan. We note also that Pfizer disclosed in its 10-K for fiscal 2013 that during that year it sold medical products for use in Syria, and Pfizer filed as an exhibit to its 10-K for fiscal 2015 a Global Performance Plan which appears to describe the compensation calculation for employees’ performance related to Sudan and Syria. Sudan and Syria are designated by the Department of State as state sponsors of terrorism, and are subject to U.S. economic sanctions and export controls. Please describe to us the nature and extent of any past, current, and anticipated contacts with Sudan and Syria, whether through subsidiaries, distributors, customers or other direct or indirect arrangements. You should describe any products, information or technology you have provided to Sudan or Syria, directly or indirectly, and any agreements, commercial arrangements, or other contacts you have had with the governments of those countries or entities they control.

ICUI answered
We have been advised that neither ICU nor any of its subsidiaries is aware of having any past, current or anticipated direct contacts with Sudan or Syria. ICU has twelve employees and three sales agents located in South Africa; it has no employees or physical assets located in the Middle East. Neither ICU nor any of its subsidiaries has directly provided to Sudan or Syria any products, information or technology.
Rest of the answer

Neither ICU nor any of its subsidiaries has had any agreements, arrangements, or contacts of any kind with the governments of Sudan or Syria, or with any entities known to be controlled by either of those governments.

In addition, we have been advised that neither ICU nor any of its subsidiaries is aware of any indirect contacts, current or anticipated, with Sudan or Syria. ICU sells its products to other medical device manufacturers, including Hospira, Inc. (“Hospira”), which Pfizer acquired in September 2015 and which now operates as a subsidiary of Pfizer. ICU does not currently, and has not historically, sold its products directly to Pfizer, other than an insignificant amount to a Pfizer entity in Spain and its sales to Hospira. ICU has not received any information from Pfizer, Hospira, the U.S. government or any other source indicating that any ICU products have been sold in or diverted to Sudan or Syria, whether by Hospira, Pfizer (either as its parent entity or prior to its acquisition of Hospira) or through any other channel.

Read in the reply
General
SEC asked (2)
Please discuss the materiality of any contacts with Sudan and Syria you describe in response to the comment above, and whether those contacts constitute a material investment risk for your security holders. You should address materiality in quantitative terms, including the approximate dollar amounts of any associated revenues, assets, and liabilities for the last three fiscal years and the subsequent interim
Rest of the question

period. Also, address materiality in terms of qualitative factors that a reasonable investor would deem important in making an investment decision, including the potential impact of corporate activities upon a company's reputation and share value. Various state and municipal governments, universities, and other investors have proposed or adopted divestment or similar initiatives regarding investment in companies that do business with U.S.- designated state sponsors of terrorism. You should address the potential impact of the investor sentiment evidenced by such actions directed toward companies that have operations associated with Sudan and Syria.

ICUI answered
As described above, ICU is not aware of any direct or indirect past, current or anticipated contacts with Sudan or Syria, the governments thereof or any entities known to be controlled by those governments, and therefore is not aware of any such contacts that could be considered to be material in quantitative or qualitative terms.

The Company acknowledges that it is responsible for the adequacy and accuracy of the disclosure in the 10-K; that Staff comments or changes to disclosure in response to Staff comments do not foreclose the Securities and Exchange Commission from taking any action
Rest of the answer

with respect to the filing; and that the Company may not assert Staff comments as a defense in any proceeding initiated by the Securities and Exchange Commission or any person under the federal securities laws of the United States.

Read in the reply

Also in this review: closing letter, 2016-07-19

From the SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), 13 letters filed since 2016-06-27. Questions and answers are matched by their numbers; topics come from words in each question. The reports are compared word for word (same form, before the first SEC letter against the first report after the company's reply). No AI.

Sources

The SEC's correspondence on EDGAR: staff letters (form UPLOAD) and company letters (form CORRESP), matched question by question. No AI.

Also

Filings: the letters in the filing list.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/ICUI/export.csv") into a cell.

Next in Owners and insiders:Insider trades
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.